Prognostic Value of Arterial Spin Labeling Brain Perfusion MRI in Term Neonates With Hypoxic-ischemic Encephalopathy (BBASL)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France
- CHU Bordeaux
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- neonates with a term ≥ 36 weeks of amenorrhea and birth weight ≥ 1800 g.
presenting with perinatal asphyxia defined as combination of:
- an acute perinatal event (such as placental abruption, cord prolapse, and/or severe foetal heart rate abnormalities);
and at least one of the following criteria:
- Apgar score ≤ 5 at 10 minutes of life,
- mask ventilation or intubation at 10 minutes of life,
- metabolic acidosis defined as pH < 7 or base deficit ≥ 16 mmol/L or lactates ≥ 11 mmol/L within the first 60 minutes of life on cord or other arterial venous or capillary blood sample.
- patient treated or not with therapeutic hypothermia for 72 hours.
- affiliated patient or beneficiary of a social security scheme.
- informed and signed parental consent.
Exclusion Criteria:
- perinatal arterial ischemic stroke.
- congenital neuro-metabolic disorder.
- severe malformative abnormalities.
- MRI contra-indication.
- Poor understanding of the holders of parental authority
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arterial Spin Labeling sequence
ASL sequence added to the usual care brain MRI
|
ASL sequence added to the usual care brain MRI
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical outcome
Time Frame: 3 months of life (Month 3)
|
judged as favorable, or as adverse in case of death or cerebral palsy
|
3 months of life (Month 3)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical outcome
Time Frame: Month 6, Month 12
|
judged as favorable or as adverse
|
Month 6, Month 12
|
|
Prognostic performances of ASL
Time Frame: Baseline
|
Prognostic performances of ASL in comparison with routinely used MRI parameters
|
Baseline
|
|
Quality of ASL sequences
Time Frame: Baseline
|
according to visual analysis of artifacts and number of negative voxels
|
Baseline
|
|
Inter-observer agreement of the interpretation of the perfusion data
Time Frame: Baseline
|
Intra Class correlation coefficient
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHUBX 2020/01
- 2020-A00299-30 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.